CLOSED
NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%

Piramal Pharma Acquires Majority Stake in Yapan Bio

By ThePip DeskPiramal Pharma Acquires Majority Stake in Yapan Bio

Piramal Pharma strengthens its position by acquiring a majority stake in Yapan Bio, making it a subsidiary and enhancing its large molecule capabilities.

Piramal Pharma has finalized the acquisition of an additional 40.67% stake in Yapan Bio, effectively integrating the company as a new subsidiary. This strategic move significantly increases Piramal Pharma’s control and operational alignment with Yapan Bio.

Key Acquisition Details

  • Piramal Pharma acquired an additional 40.67% stake.
  • This involved 1,46,400 equity shares, each valued at Rs 10.
  • The aggregate cash consideration amounted to approximately Rs 76 crore.
  • Piramal Pharma’s total shareholding in Yapan Bio has risen from 33.33% to 74.00%.

Following this transaction, Yapan Bio transitions from an associate company to a full subsidiary of Piramal Pharma. The increased stake positions Yapan Bio directly within Piramal Pharma’s operational structure.

Strategic Integration

This acquisition is set to fully embed Yapan’s advanced large molecule capabilities into Piramal Pharma’s existing integrated service offerings. The integration aims to enhance the company’s ability to develop and scale complex biologic therapies with greater efficiency.

Piramal Pharma offers comprehensive end-to-end pharma services to its clients, alongside a diverse portfolio of differentiated pharma products distributed across both domestic and global networks.

Home/business/Article